Brii BiosciencesFRA:7SS -7.76%33 3-Year ROIIC % is 3,458.28 as of Dec. 2025. GuruFocus rates FRA:7SS with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 1,318 Biotechnology companies, Brii Biosciences ranks better than 98.1% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Brii Biosciences's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 3,458.28%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Brii Biosciences's 3-Year ROIIC % or its related term are showing as below:
FRA:7SS's 3-Year ROIIC % is ranked better than 98.1% of 1318
companies
in the Biotechnology industry
Industry Median: -4.63
vs FRA:7SS: 3458.28
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Brii Biosciences 3-Year ROIIC % Related Terms
Brii Biosciences 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Brii Biosciences's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7SS vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Brii Biosciences's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brii Biosciences 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Brii Biosciences's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Brii Biosciences's 3-Year ROIIC % falls into.
Brii Biosciences's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -34.775 (Dec. 2025) - -69.623 (Dec. 2022) )
/
( 49.067 (Dec. 2025) - 53.305 (Dec. 2022) )
=
34.848
/
-4.2380000000001
=
-822.27%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Brii Biosciences (FRA:7SS) has a 3-Year ROIIC % of 3,458.28 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Brii Biosciences and its competitors. According to the industry distribution chart, Brii Biosciences ranks #25 out of 1318 companies in the Biotechnology industry, placing it in the top 1.9%.
Is Brii Biosciences' 3-Year ROIIC % too high?
Brii Biosciences' current 3-Year ROIIC % is 3,458.28. Based on the distribution chart, Brii Biosciences ranks #25 out of 1318 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Brii Biosciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Brii Biosciences' 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Brii Biosciences ranks #25 out of 1318 companies for 3-Year ROIIC %. This places Brii Biosciences in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Brii Biosciences and its competitors. Brii Biosciences's current 3-Year ROIIC % is 3,458.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brii Biosciences stock overvalued right now?
Brii Biosciences (FRA:7SS) has a current 3-Year ROIIC % of 3,458.28. The current 3-Year ROIIC % is 3,458.28. Brii Biosciences' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Brii Biosciences (FRA:7SS), the current 3-Year ROIIC % is 3,458.28 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AddressNo. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed to developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as CNS diseases, which have public health burdens in China and around the world. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
33GF Score
Get the complete analysis for FRA:7SS
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7SS has been successfully added to your 
